BioCentury | Mar 24, 2021
Emerging Company Profile

Dunad: Expanding protein degradation beyond E3 ligase

...Atlantic. Dunad was spun out of the University of Toronto...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...with participation by Shanghai FTZ Fund, Suzhou Longmen Venture Capital and Chengwei Capital.Series A for University of Toronto...
...Ventures to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion. The University of Toronto...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...from its wholly-owned pipeline toward the clinic.Spun out of the Sunnybrook Research Institute and the University of Toronto...
...scientist at Sunnybrook; and Peter Zandstra, the CSO of CCRM. Both are professors at the University of Toronto...
BioCentury | Jan 9, 2021
Product Development

The unfolding dosing controversy for COVID vaccines

...immunity.According to modeling from scientists at the University of Toronto...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...the African sleeping sickness vaccine, and a University of Toronto...
...Zinc finger DHHC-type containing 7 Karen Tkach Tuzman Yale University University of Toronto Bright...
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...in patients with less severe disease. The double-blind, University of Toronto-led...
...viral shedding in patients with mild, uncomplicated infections. University of Toronto...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...Brain cancer CAR T therapy A McMaster University and University of Toronto team revealed in a Cell Stem...
BioCentury | May 29, 2020
Distillery Therapeutics

The mitochondrial peptidase NLN identified as AML target

...CONTACT: Aaron D. Schimmer, University of Toronto, Toronto, Ontario; Princess Margaret Cancer Centre, Toronto, Ontario email: aaron.schimmer@uhn.ca Claire Quang University of Toronto...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

...published online Jan. 7, 2020 doi:10.1016/j.chembiol.2019.12.008 CONTACT: Leah E. Cowen, University of Toronto, Toronto, Ontario email: leah.cowen@utoronto.ca Claire Quang University of Toronto...
BioCentury | Jan 10, 2020
Emerging Company Profile

Empirica: Building a new model for brain cancer

...mAbs, bispecific T cell engaging antibodies and CAR T cells using antibodies licensed from the University of Toronto...
...Cancer Clinical status: Preclinical Founded: July 2018 by Sheila Singh and Jason Moffat University collaborators: University of Toronto...
Items per page:
1 - 10 of 278
BioCentury | Mar 24, 2021
Emerging Company Profile

Dunad: Expanding protein degradation beyond E3 ligase

...Atlantic. Dunad was spun out of the University of Toronto...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...with participation by Shanghai FTZ Fund, Suzhou Longmen Venture Capital and Chengwei Capital.Series A for University of Toronto...
...Ventures to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion. The University of Toronto...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...from its wholly-owned pipeline toward the clinic.Spun out of the Sunnybrook Research Institute and the University of Toronto...
...scientist at Sunnybrook; and Peter Zandstra, the CSO of CCRM. Both are professors at the University of Toronto...
BioCentury | Jan 9, 2021
Product Development

The unfolding dosing controversy for COVID vaccines

...immunity.According to modeling from scientists at the University of Toronto...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...the African sleeping sickness vaccine, and a University of Toronto...
...Zinc finger DHHC-type containing 7 Karen Tkach Tuzman Yale University University of Toronto Bright...
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...in patients with less severe disease. The double-blind, University of Toronto-led...
...viral shedding in patients with mild, uncomplicated infections. University of Toronto...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...Brain cancer CAR T therapy A McMaster University and University of Toronto team revealed in a Cell Stem...
BioCentury | May 29, 2020
Distillery Therapeutics

The mitochondrial peptidase NLN identified as AML target

...CONTACT: Aaron D. Schimmer, University of Toronto, Toronto, Ontario; Princess Margaret Cancer Centre, Toronto, Ontario email: aaron.schimmer@uhn.ca Claire Quang University of Toronto...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

...published online Jan. 7, 2020 doi:10.1016/j.chembiol.2019.12.008 CONTACT: Leah E. Cowen, University of Toronto, Toronto, Ontario email: leah.cowen@utoronto.ca Claire Quang University of Toronto...
BioCentury | Jan 10, 2020
Emerging Company Profile

Empirica: Building a new model for brain cancer

...mAbs, bispecific T cell engaging antibodies and CAR T cells using antibodies licensed from the University of Toronto...
...Cancer Clinical status: Preclinical Founded: July 2018 by Sheila Singh and Jason Moffat University collaborators: University of Toronto...
Items per page:
1 - 10 of 278